A review of the clinical evidence for intensity-modulated radiotherapy

Clinical Oncology

Volumn 22, Issue 8, 2010, Pages 643-657

  Staffurth, J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Comparative study; Evidence; IMRT; Intensity modulated radiotherapy; Randomised clinical trial

Indexed keywords

ANTHRACYCLINE; BICALUTAMIDE; CISPLATIN; ETOPOSIDE; GOSERELIN; IODINE 125; TAXANE DERIVATIVE;

ADVANCED CANCER; ANUS CANCER; ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DYSPHAGIA; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HUMAN; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL RESEARCH; MEDLINE; MEDULLOBLASTOMA; MOUTH CANCER; NASOPHARYNX CANCER; OUTCOME ASSESSMENT; PAROTID GLAND; PATIENT SAFETY; PHARYNX CANCER; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RANDOMIZATION; RECTUM INJURY; SALIVA; SKIN FIBROSIS; SKIN TOXICITY; TREATMENT PLANNING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; XEROSTOMIA;

HUMANS; NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77956266565     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.06.013     Document Type: Article

References (136)

1. Veldeman L., Madani I., Hulstaert F., De Meerleer G., Mareel M., De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9(4):367-375.
2. National Radiotherapy Advisory Group Radiotherapy: developing a world class service for England. Report to Ministers Available at:. http://www.cancer.nhs.uk/nrag.htm.
3. Mayles P. Introduction to the special issue on the technology of radiotherapy. J Clin Oncol 2010, 22:621-622.
4. Whitton A., Warde P., Sharpe M., et al. Organisational standards for the delivery of intensity-modulated radiation therapy in Ontario. Clin Oncol (R Coll Radiol) 2009, 21(3):192-203.
5. Cannon D.M., Lee N.Y. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 70(3):660-665.
6. Hall E.J., Wuu C.S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003, 56(1):83-88.
7. Ruben J.D., Davis S., Evans C., et al. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. Int J Radiat Oncol Biol Phys 2008, 70(5):1530-1536.
8. Miles E.A., Clark C.H., Urbano M.T., et al. The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol 2005, 77(3):241-246.
9. Nutting C., A'Hern R., Rogers M., et al. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J Clin Oncol 2009, 27(Suppl. 18):LBA006.
10. http://controlled-trials.com/mrct/.
11. International Atomic Energy Agency. Transition from 2-D radiotherapy to 3-D conformal and intensity modulated radiotherapy. IAEA Technical Document, 2008.
12. Mayles W.P., Yarnold J.R., Webb S. Improved dose homogeneity in the breast using tissue compensators. Radiother Oncol 1991, 22(4):248-251.
13. Wilkinson J.M., Lewis J., Lawrence G.P., Lucraft H., Murphy E. Craniospinal irradiation using a forward planned segmented field technique. Br J Radiol 2007, 80:209-215.
14. Donovan E.M., Johnson U., Shentall G., Evans P.M., Neal A.J., Yarnold J.R. Evaluation of compensation in breast radiotherapy: a planning study using multiple static fields. Int J Radiat Oncol Biol Phys 2000, 46(3):671-679.
15. MacDonald S., Bernard S., Balogh A., Spencer D., Sawchuk S. Electronic compensation using multileaf collimation for involved field radiation to the neck and mediastinum in non-Hodgkin's lymphoma and Hodgkin's lymphoma. Med Dosim 2005, 30(2):59-64.
16. Lee N., Akazawa C., Akazawa P., et al. A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 59(2):584-594.
17. Poon I., Xia P., Weinberg V., et al. A treatment planning analysis of inverse-planned and forward-planned intensity-modulated radiation therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007, 69(5):1625-1633.
18. Vaarkamp J., Adams E.J., Warrington A.P., Dearnaley D.P. A comparison of forward and inverse planned conformal, multi segment and intensity modulated radiotherapy for the treatment of prostate and pelvic nodes. Radiother Oncol 2004, 73(1):65-72.
19. Donovan E., Bleakley N., Denholm E., et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007, 82(3):254-264.
20. Evans P.M., Hansen V.N., Mayles W.P., Swindell W., Torr M., Yarnold J.R. Design of compensators for breast radiotherapy using electronic portal imaging. Radiother Oncol 1995, 37(1):43-54.
21. Barnett G., Wilkinson J., Moody A., et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol 2009, 92(1):34-41.
22. Li Y., Taylor J.M., Ten Haken R.K., Eisbruch A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2007, 67(3):660-669.
23. Marmiroli L., Salvi G., Caiazza A., et al. Dose and volume impact on radiation-induced xerostomia. Rays 2005, 30(2):145-148.
24. Feng M., Jabbari S., Lin A., et al. Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. Radiother Oncol 2005, 77(1):32-38.
25. Kam M.K., Leung S.F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25(31):4873-4879.
26. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
27. Newbold K., Partridge M., Cook G., et al. Advanced imaging applied to radiotherapy planning in head and neck cancer: a clinical review. Br J Radiol 2006, 79:554-561.
28. Vanderstraeten B., Duthoy W., De Gersem W., De Neve W., Thierens H. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006, 79:249-258.
29. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66(4):981-991.
30. Laskar S., Bahl G., Muckaden M., et al. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72(3):728-736.
31. Wolden S.L., Chen W.C., Pfister D.G., Kraus D.H., Berry S.L., Zelefsky M.J. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006, 64(1):57-62.
32. Hsiung C.Y., Ting H.M., Huang H.Y., Lee C.H., Huang E.Y., Hsu H.C. Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma: preserved parotid function after IMRT on quantitative salivary scintigraphy, and comparison with historical data after conventional radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66(2):454-461.
33. Fang F.M., Tsai W.L., Chen H.C., et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 2007, 109:313-321.
34. Fang F.M., Chien C.Y., Tsai W.L., et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys 2008, 72(2):356-364.
35. Braam P.M., Terhaard C.H.J., Roesink J.M., Raaijmakers C.P.J. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66(4):975-980.
36. Chao K.S., Majhail N., Huang C.J., et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001, 61(3):275-280.
37. Daly M.E., Lieskovsky Y., Pawlicki T., et al. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 2007, 29:211-220.
38. Graff P., Lapeyre M., Desandes E., et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67(5):1309-1317.
39. Jabbari S., Kim H.M., Feng M., et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 2005, 63(3):725-731.
40. Lee N.Y., de Arruda F.F., Puri D.R., et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66(4):966-974.
41. Münter M.W., Hoffner S., Hof H., et al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. Int J Radiat Oncol Biol Phys 2007, 67(3):651-659.
42. Pacholke H.D., Amdur R.J., Morris C.G., et al. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol 2005, 28(1):351-358.
43. Rades D., Fehlauer F., Wroblesky J., Albers D., Schild S.E., Schmidt R. Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncol 2007, 43(6):535-543.
44. Rothschild S., Studer G., Seifert B., et al. PET/CT staging followed by intensity-modulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison. Radiat Oncol 2007, 2:22.
45. Studer G., Zwahlen R.A., Graetz K.W., Davis B.J., Glanzmann C. IMRT in oral cavity cancer. Radiat Oncol 2007, 2:16.
46. van Rij C.M., Oughlane-Heemsbergen W.D., Ackerstaff A.H., Lamers E.A., Balm A.J., Rasch C.R. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol 2008, 3:41.
47. Vergeer M.R., Doornaert P.A., Rietveld D.H., Leemans C.R., Slotman B.J., Langendijk J.A. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2008, 74(1):1-8.
48. Yao M., Karnell L.H., Funk G.F., Lu H., Dornfeld K., Buatti J.M. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007, 69(5):1354-1360.
49. Milano M.T., Yokes E.E., Kao J., et al. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol 2006, 28(5):1141-1151.
50. Duthoy W., Boterberg T., Claus F., et al. Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer 2005, 104(1):71-82.
51. Chen A.M., Daly M.E., Bucci M.K., et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys 2007, 69:141-147.
52. Hoppe B.S., Stegman L.D., Zelefsky M.J., et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting-the MSKCC experience. Int J Radiat Oncol Biol Phys 2007, 67:691-702.
53. Lee N., Chan K., Bekelman J.E., et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 68(3):731-740.
54. Madani I., Vakaet L., Bonte K., Boterberg T., De Neve W. Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer. Int J Radiat Oncol Biol Phys 2008, 71(4):1158-1166.
55. National Collaborating Centre for Cancer Prostate cancer: diagnosis and treatment 2008, National Collaborating Centre for Cancer, Cardiff.
56. Fiorino C., Valdagni R., Rancati T., Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009, 93(2):153-167.
57. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(1):67-74.
58. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8(6):475-487.
59. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92(3):488-498.
60. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006, 24(13):1990-1996.
61. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239.
62. Heemsbergen W.D., Hoogeman M.S., Witte M.G., Peeters S.T., Incrocci L., Lebesque J.V. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68Gy versus 78Gy. Int J Radiat Oncol Biol Phys 2007, 67(5):1418-1424.
63. de Crevoisier R., Tucker S.L., Dong L., et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62(4):965-973.
64. Engels B., Soete G., Verellen D., Storme G. Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys 2009, 74(2):383-391.
65. Khoo V.S., Dearnaley D.P. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer-the CHHiP trial. Clin Oncol (R Coll Radiol) 2008, 20(1):12-14.
66. De Meerleer G.O., Vakaet L.A., De Gersem W.R., De Wagter C., De Naeyer B., De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 2000, 47(3):639-648.
67. Nutting C.M., Convery D.J., Cosgrove V.P., et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48(3):649-656.
68. Luxton G., Hancock S.L., Boyer A.L. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004, 59(1):267-284.
69. Ashman J.B., Zelefsky M.J., Hunt M.S., Leibel S.A., Fuks Z. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63(3):765-771.
70. Kao J., Turian J., Meyers A., et al. Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br J Radiol 2004, 77:129-136.
71. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000, 55(3):241-249.
72. Guerrero Urbano M, Norman A, Adams A, et al. A phase 1 dose escalation study of intensity modulated radiotherapy (IMRT) to treat the prostate and pelvic nodes in patients with locally advanced prostate cancer. Proc Multidisciplinary Prostate Cancer Symposium 2005;1:123.
73. Cozzarini C., Fiorino C., Di Muzio N., et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol 2007, 84(2):164-170.
74. Lawton C.A., Michalski J., El-Naqa I., et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2008, 74(2):383-387.
75. Vora S.A., Wong W.W., Schild S.E., Ezzell G.A., Halyard M.Y. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68(4):1053-1058.
76. Kupelian P.A.R., Reddy C.A., Carlson T.P., Altsman K.A., Willoughby T.R. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70Gy at 2.5Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:904-912.
77. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166(3):876-881.
78. Morgan P., Ruth K., Horwitz E., Buyyounouski M., Uzzo R., Pollack A. A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: toxicity and outcomes. Int J Radiat Oncol Biol Phys 2007, 69(3):S319.
79. Al-Mamgani A., Heemsbergen W.D., Peeters S.T., Lebesque J.V. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73(3):685-691.
80. Sanguineti G., Cavey M.L., Endres E.J., et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76Gy?. Strahlenther Onkol 2006, 182(9):543-549.
81. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 80:1124-1129.
82. Kirichenko A., Ruth K., Horwitz E., et al. Intensity modulated radiation therapy for prostate cancer: preliminary results on treatment morbidity compared to 3-D conformal radiation therapy. Int J Radiat Oncol Biol Phys 2006, 66(3):S326.
83. Sharma N.K., Li T., Horwitz E.M., Pollack A., Buyyounouski M.K. Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007, 69(3):S10.
84. Martinez A., Yan D., Brabbins D., et al. Acute and chronic toxicity of adaptive image guided radiation therapy (A-IGRT) delivered with 3D-conformal technique (3D-CRT) vs. intensity modulation (IMRT) in 728 prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69(3):S317.
85. Jani A.B., Su A., Correa D., Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007, 10(1):82-86.
86. Shu H.K., Lee T.T., Vigneauly E., et al. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 2001, 57(1):102-107.
87. Boehmer D., Herschel R., Badakhshi H., Eichwurzel I., Wernecke K., Budach V. Matched pair analysis of patients with prostate cancer treated with IMRT or 3-D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66(3):S394.
88. Su A.W., Jani A.B. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol 2007, 30(3):215-219.
89. Namiki S., Ishidoya S., Tochigi T., et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 2006, 36(4):224-230.
90. Lips I., Dehnad H., Kruger A.B., et al. Health-related quality of life in patients with locally advanced prostate cancer after 76Gy intensity-modulated radiotherapy vs 70Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 2007, 69:656-661.
91. Yoshimura K., Kamoto T., Nakamura E., et al. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy. Prostate Cancer Prostatic Dis 2006, 10:288-292.
92. Zelefsky M.J., Yamada Y., Hunt M., Cohen G.N., Shippy A.M., Zaider M. Comparison of 7-year outcomes between LDR brachytherapy and high dose IMRT for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 69(3):S178.
93. 125I permanent implant. Int J Radiat Oncol Biol Phys 2008, 71(2):338-345.
94. Deutsch I., Zelefsky M.J., Cahlon O., et al. Comparison of PSA relapse free survival in patients treated with ultra-high dose IMRT versus combination HDR brachytherapy and IMRT. Int J Radiat Oncol Biol Phys 2008, 69(3):S135.
95. Su A.W., Milano M.T., Jani A.B. IMRT versus conventional whole pelvis radiotherapy for prostate cancer: planning comparison and analysis of acute toxicity. Int J Radiat Oncol Biol Phys 2005, 63(2):S312.
96. Jani A.B., Su A., Milano M.T. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology 2006, 67(1):147-151.
97. Jani A.B., Gratzle J., Correa D. Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer. Technol Cancer Res Treat 2007, 6(1):11-15.
98. Alongi F., Fiorino C., Cozzarini C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009, 93:207-212.
99. Pignol J.P., Olivotto I., Rakovitch E., et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008, 26(13):2085-2092.
100. Freedman G., Anderson P.R., Li J., et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol 2006, 29(1):66-70.
101. Harsolia A., Kestin L., Grills I., et al. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68(5):1375-1380.
102. McDonald M.W., Godette K.D., Butker E.K., Davis L.W., Johnstone P.A. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis. Int J Radiat Oncol Biol Phys 2008, 72(4):1031-1040.
103. Morganti A.G., Cilla S., Valentini V., et al. Phase I-II studies on accelerated IMRT in breast carcinoma: technical comparison and acute toxicity in 332 patients. Radiother Oncol 2009, 90(1):86-92.
104. Blake P., Swart A.M., Orton J., et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009, 373(9658):137-146.
105. Roeske J.C., Lujan A., Rotmensch J., Waggoner S.E., Yamada D., Mundt A.J. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2000, 48(5):1613-1621.
106. Lujan A.E., Mundt A.J., Yamada S.D., Rotmensch J., Roeske J.C. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57(2):516-521.
107. Esthappan J., Chaudhari S., Santanam L., et al. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2008, 72(4):1134-1139.
108. Small W., Mell L.K., Anderson P., et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008, 71(2):428-434.
109. Taylor A., Rockall A.G., Reznek R.H., Powell M.E. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63(5):1604-1612.
110. Mundt A.J., Roeske J.C., Lujan A.E., et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 2001, 82(3):456-463.
111. Brixey C.J., Roeske J.C., Lujan A.E., Yamada S.D., Rotmensch J., Mundt A.J. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 54(5):1388-1396.
112. Mundt A.J., Mell L.K., Roeske J.C. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2003, 56(5):1354-1360.
113. Chen M.F., Tseng C.J., Tseng C.C., Kuo Y.C., Yu C.Y., Chen W.C. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67(5):1438-1444.
114. Bjork-Eriksson T., Glimelius B. The potential of proton beam therapy in paediatric cancer. Acta Oncol 2005, 44(8):871-875.
115. Fuller C.D., Choi M., Forthuber B., et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol 2007, 2:26.
116. Iuchi T., Hatano K., Narita Y., Kodama T., Yamaki T., Osato K. Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 2006, 64(5):1317-1324.
117. Huang E., Teh B.S., Strother D.R., et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002, 52(3):599-605.
118. Mell L.K., Schomas D.A., Salama J.K., et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70(5):1431-1437.
119. Saarilahti K., Arponen P., Vaalavirta L., Tenhunen M. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008, 87(3):383-390.
120. Myerson R.J., Garofalo M.C., Naqa I.E., et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a Radiation Therapy Oncology Group Consensus Panel contouring atlas. Int J Radiat Oncol Biol Phys 2008, 72(1):S71.
121. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45(2):323-329.
122. Yom S.S., Liao Z., Liu H.H., et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68(1):94-102.
123. Nutting C.M. Preliminary results from clinical trials. Radiother Oncol 2008, 88(S2):S174.
124. Schoenfeld G.O., Amdur R.J., Morris C.G., Li J.G., Hinerman R.W., Mendenhall W.M. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 71(2):377-385.
125. Eisbruch A., Marsh L.H., Dawson L.A., et al. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004, 59(1):28-42.
126. David M.B., Eisbruch A. Delineating neck targets for intensity-modulated radiation therapy of head and neck cancer. What we learned from marginal recurrences?. Front Radiat Ther Oncol 2007, 40:193-207.
127. Sanguineti G., Gunn G.B., Endres E.J., Chaljub G., Cheruvu P., Parker B. Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008, 72(3):737-746.
128. Yao M., Chang K., Funk G.F., et al. The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy-the University of Iowa experience. Int J Radiat Oncol Biol Phys 2007, 67(5):1332-1341.
129. Viani G.A., Stefano E.J., Afonso S.L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009, 74(5):1405-1418.
130. Dearnaley D., Sumo G., Syndikus I., et al. Initial toxicity results of the phase III Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) trial (ISRCTN97182923). Genitourinary ASCO Proceedings 2009, (abstract 303).
131. Brabbins D.S., Kestin L., Yan D., et al. Improvement in clinical outcomes with prostate radiotherapy at a single institution in the PSA era. Int J Radiat Oncol Biol Phys 2008, 72(1):S318.
132. Rawlins M. De Testimonio: on the evidence for decisions about the use of therapeutic interventions. Clin Med 2008, 8(6):579-588.
133. Mayles WPM. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol 2010;22:639-642.
134. Williams MV, Cooper T, Mackay R, Staffurth J, Routsis D, Bornet N. The implementation of intensity-modulated radiotherapy in the UK. Clin Oncol 2010;22:623-628.
135. Maughan TS, Illidge TM, Hoskin P, et al. Radiotherapy research priorities for the UK. Clin Oncol 2010;22:707-709.
136. http://rttrialsqa.dnsalias.org.